0RC7.L - Hansa Biopharma AB (publ)

LSE - LSE Prezzo differito. Valuta in SEK.

Hansa Biopharma AB (publ)

ScheelevAegen 22
Lund 223 63
46 46 16 56 70

Impiegati a tempo pieno159

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Søren Tulstrup M.ScPres & CEO15,26MN/D1965
Mr. Donato SpotaCFO & Sr. VPN/DN/D1971
Dr. Christian KjellmanSr. VP, Chief Scientific Officer & COON/DN/D1967
Ms. Eva-Maria JoedVP of Fin. & Admin.N/DN/D1969
Mr. Klaus SindahlVP & Head of Investor RelationsN/DN/DN/D
Ms. Anne Säfström LannerSr. VP & Chief HR OfficerN/DN/D1969
Mr. Emanuel BjörneVP & Head of Bus. Devel.N/DN/D1973
Dr. Lena WinstedtHead of ScienceN/DN/D1969
Ms. Vincenza Nigro M.B.A.VP & Head of Medical AffairsN/DN/DN/D
Dr. Achim Kaufhold M.D., Ph.D.Sr. VP & Chief Medical OfficerN/DN/D1958
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.


Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Hansa Biopharma AB (publ) al 1 giugno 2023 è 2. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.